|
Mechanism50S subunit inhibitors [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date20 Jun 2014 |
Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
100 Clinical Results associated with Trius Therapeutics LLC
0 Patents (Medical) associated with Trius Therapeutics LLC
100 Deals associated with Trius Therapeutics LLC
100 Translational Medicine associated with Trius Therapeutics LLC